WOONSOCKET, Rhode Island — CVS Health, one of the largest healthcare companies in the United States, announced on Wednesday, November 4, 2026, that it intends to split itself into two independent, publicly traded companies, separating its roughly 9,000 retail pharmacies from its Aetna health insurance business and its CVS Caremark pharmacy-benefit operations. The company said the decision followed a comprehensive strategic review by its board of directors, and that the separation is expected to be completed in the first half of 2028.

Source: CVS Health news release, Nov 4, 2026

Reuters described the move as a major unwinding of the $117 billion healthcare conglomerate CVS spent years building. One company, which will keep the CVS Health name for now, will hold the insurance, pharmacy-benefit and care-delivery businesses. The second, to be called CVS Pharmacy, will be a standalone national retail pharmacy chain — the first time CVS will stand alone as a pharmacy company since it bought Caremark in 2006.

Source: Reuters, Nov 4, 2026

How the two companies will be built

The healthcare solutions company — referred to in the interim as CVS Health — will comprise health insurer Aetna, pharmacy benefit manager CVS Caremark, CVS Specialty, primary-care provider Oak Street Health and in-home health evaluations business Signify Health. CVS said this combination will keep together the connections that, in its words, drive value for clients and members by lowering costs while improving health outcomes and experiences.

The second company, CVS Pharmacy, will comprise approximately 9,000 CVS pharmacies, the mail pharmacy, MinuteClinic walk-in clinics including virtual care, and the Health100 technology services business. CVS called the pharmacy chain 'the front door to health and care in our country' and 'the most frequently accessed consumer health touchpoint,' and said the standalone company will expand the services provided by its nearly 30,000 pharmacists and pursue a wider set of partnerships with payers, pharmacy benefit managers and manufacturers.

David Joyner, currently chairman and chief executive of CVS Health, will be chairman and CEO of the healthcare solutions company after the split. Prem Shah, currently group president of CVS Health, will become CEO of CVS Pharmacy. Additional leadership positions and board members will be announced at a later date, the company said.

Why now: two stronger years, and a regulatory shadow

'Our history is defined by proactively evolving to stay ahead of what's next in healthcare,' Joyner said in the announcement. 'Over the last two years, we have made meaningful progress: we built a world-class leadership team, strengthened our financials, revitalized operations across the enterprise, and drove total shareholder return. From a position of strength, and a focus on the long term, we plan to create two focused companies to improve consumer engagement, affordability, and care coordination.' Reuters reported Joyner noted the company had beaten Wall Street expectations for eight straight quarters, including Wednesday's third-quarter profit of $2.09 per share against analysts' average estimate of $1.65, according to LSEG data.

Analysts, however, read a defensive motive as well. Years of industry consolidation have drawn criticism that combining insurers, pharmacy benefit managers and pharmacies in one company creates conflicts of interest and contributes to the highest healthcare spending in the world. 'Vertical integration at the (managed care organizations) has been coming under fire by regulators and customers alike in recent years. CVS has the most exposure to vertical integration in the industry,' Morningstar analyst Julie Utterback told Reuters, adding that management probably chose to move preemptively rather than wait for a legal or legislative decision. UBS analyst Kevin Caliendo said the split 'came as a surprise, and is perceived as happening as a defensive move against regulation rather than an offensive move.'

Background: the conglomerate being unwound

The split reverses two decades of deal-making. CVS bought the Caremark pharmacy benefit manager in 2006 — a deal Barclays analyst Andrew Mok noted was sold at the time on at least $500 million of expected synergies — and went on to a stream of acquisitions over 20 years, including the $78 billion purchase of health insurer Aetna in 2018, Reuters reported. CVS had already explored options including a potential breakup in 2024. The pressures are industry-wide: CVS drugstores face payment pressure and competition from Amazon and other online pharmacies as prescription delivery reduces store visits, and rival Walgreens sold its Boots pharmacy business and was acquired by private equity firm Sycamore Partners last year after a prolonged sale process.

What it means for patients, members and pharmacy workers

For the millions of people who use CVS every week — including Punjabi diaspora families across the United States who rely on neighbourhood pharmacies for prescriptions, vaccinations and MinuteClinic visits — nothing changes immediately. CVS said customers, patients and clients 'will continue to receive their medicine, care, benefits and services, uninterrupted,' and that until the separation is completed it will continue to operate, compete and serve customers as it does today. As of September 30, 2026, the company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics, a pharmacy benefits manager with approximately 87 million plan members, and health insurance products serving an estimated 37 million people.

What happens next

The separation is not final. It remains subject to customary conditions, including final approval by the CVS Health board of directors, effectiveness of a Form 10 registration statement filed with the U.S. Securities and Exchange Commission, and receipt of customary confirmation that the split will be tax-free to CVS Health and its shareholders for U.S. federal income tax purposes. On completion, shareholders will own shares in both companies, and both are expected to carry a solid investment-grade rating with strong free cash flow and an attractive dividend, the company said. Goldman Sachs & Co. LLC is lead financial and strategic advisor, Consello is also advising, and Wachtell, Lipton, Rosen & Katz is legal counsel. CVS said it will provide additional information as the process progresses.